Centers | ||
|
|
|
EU-OPENSCREEN | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | Therapeutic Accelerator Program (TAP) |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Test |
Partnerships |
Events |
Jobs |
UCB To Fund "Mining the Human Microbiome" Project at HarvardUCB as agreed to fund and support a third research project called "Mining the Human Microbiome" as part of the UCB-Harvard Research Alliance. UCB will be providing $4.5 million over a period of three years to immunologists at Harvard to study the... View all Merck Establishes New Center in San Diego with Academic ResearchersMerck Pharmaceuticals has committed to fund $90 million over period of seven years to establish California Institute for Biomedical Research (Calibr) in San Diego, California. The new center will be led by Peter Schulz from the Scripps Research... View all GSK and Yale to partner on drug discovery developmentGlaxoSmithKline (GSK) and Yale University will partner to design a new class of molecules to target disease-causing proteins. This is the latest in a string of deals between Yale’s academic researchers and global pharmaceutical companies. View all |
No EVENTS for listing |
No Job Posts |
